These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 8592518)
1. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades. Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518 [TBL] [Abstract][Full Text] [Related]
2. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. Paschke R; Tonacchera M; Van Sande J; Parma J; Vassart G J Clin Endocrinol Metab; 1994 Dec; 79(6):1785-9. PubMed ID: 7989485 [TBL] [Abstract][Full Text] [Related]
3. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. Parma J; Duprez L; Van Sande J; Hermans J; Rocmans P; Van Vliet G; Costagliola S; Rodien P; Dumont JE; Vassart G J Clin Endocrinol Metab; 1997 Aug; 82(8):2695-701. PubMed ID: 9253356 [TBL] [Abstract][Full Text] [Related]
4. Substitutions of different regions of the third cytoplasmic loop of the thyrotropin (TSH) receptor have selective effects on constitutive, TSH-, and TSH receptor autoantibody-stimulated phosphoinositide and 3',5'-cyclic adenosine monophosphate signal generation. Kosugi S; Okajima F; Ban T; Hidaka A; Shenker A; Kohn LD Mol Endocrinol; 1993 Aug; 7(8):1009-20. PubMed ID: 7901757 [TBL] [Abstract][Full Text] [Related]
5. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas. Porcellini A; Ciullo I; Pannain S; Fenzi G; Avvedimento E Oncogene; 1995 Sep; 11(6):1089-93. PubMed ID: 7566968 [TBL] [Abstract][Full Text] [Related]
6. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Parma J; Duprez L; Van Sande J; Cochaux P; Gervy C; Mockel J; Dumont J; Vassart G Nature; 1993 Oct; 365(6447):649-51. PubMed ID: 8413627 [TBL] [Abstract][Full Text] [Related]
8. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Duprez L; Parma J; Van Sande J; Allgeier A; Leclère J; Schvartz C; Delisle MJ; Decoulx M; Orgiazzi J; Dumont J Nat Genet; 1994 Jul; 7(3):396-401. PubMed ID: 7920658 [TBL] [Abstract][Full Text] [Related]
9. Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas. Castro I; Lima L; Seoane R; Lado-Abeal J Thyroid; 2009 Jun; 19(6):645-9. PubMed ID: 19499991 [TBL] [Abstract][Full Text] [Related]
10. Thyrotropin receptor mutations in hyperfunctioning thyroid adenomas from Brazil. Nogueira CR; Kopp P; Arseven OK; Santos CL; Jameson JL; Medeiros-Neto G Thyroid; 1999 Nov; 9(11):1063-8. PubMed ID: 10595453 [TBL] [Abstract][Full Text] [Related]
11. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism. Paschke R Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020 [TBL] [Abstract][Full Text] [Related]
12. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281-->isoleucine) in the extracellular domain of the thyrotropin receptor. Kopp P; Muirhead S; Jourdain N; Gu WX; Jameson JL; Rodd C J Clin Invest; 1997 Sep; 100(6):1634-9. PubMed ID: 9294132 [TBL] [Abstract][Full Text] [Related]
13. Constitutively activating mutations of the thyrotropin receptor and thyroid disease. Führer D; Holzapfel HP; Wonerow P; Paschke R Eur J Med Res; 1996 Jul; 1(10):460-4. PubMed ID: 9438142 [TBL] [Abstract][Full Text] [Related]
14. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. Russo D; Arturi F; Suarez HG; Schlumberger M; Du Villard JA; Crocetti U; Filetti S J Clin Endocrinol Metab; 1996 Apr; 81(4):1548-51. PubMed ID: 8636365 [TBL] [Abstract][Full Text] [Related]
15. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. Persani L; Lania A; Alberti L; Romoli R; Mantovani G; Filetti S; Spada A; Conti M J Clin Endocrinol Metab; 2000 Aug; 85(8):2872-8. PubMed ID: 10946896 [TBL] [Abstract][Full Text] [Related]
16. Interactions between the extracellular domain and the extracellular loops as well as the 6th transmembrane domain are necessary for TSH receptor activation. Neumann S; Claus M; Paschke R Eur J Endocrinol; 2005 Apr; 152(4):625-34. PubMed ID: 15817920 [TBL] [Abstract][Full Text] [Related]
17. [Non-autoimmune hyperthyroidism and hyperfunctioning thyroid adenomas caused by activating mutation of the thyrotropin receptor]. Kosugi S Nihon Rinsho; 2002 Feb; 60(2):291-6. PubMed ID: 11857916 [TBL] [Abstract][Full Text] [Related]
18. The middle portion in the second cytoplasmic loop of the thyrotropin receptor plays a crucial role in adenylate cyclase activation. Kosugi S; Kohn LD; Akamizu T; Mori T Mol Endocrinol; 1994 Apr; 8(4):498-509. PubMed ID: 7914349 [TBL] [Abstract][Full Text] [Related]
19. New pathophysiological mechanisms for hyperthyroidism. Vassart G Horm Res; 1997; 48 Suppl 4():47-50. PubMed ID: 9350447 [TBL] [Abstract][Full Text] [Related]
20. Hyperfunctioning thyroid adenoma and activating mutations in the TSH receptor gene. Polak M Arch Med Res; 1999; 30(6):510-3. PubMed ID: 10714365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]